IQVIA and Veeva Announce Global Commercial & Clinical Partnership, Resolve Legal Disputes

IQVIA and Veeva’s Global Commercial and Clinical Partnership and Clearance of Legal Disputes

Announcement

Veeva Systems and IQVIA entered a long-term commercial and clinical partnership and have completed settlement of all remaining legal issues. In this global agreement, the customers can access data, service offerings, technology, and software from IQVIA and Veeva seamlessly. The partnership makes it easy for customers to effortlessly work with both companies in the clinical and commercial areas. The partnership will help expand the customer chain by double in the future.

Specification of the Key Areas Strengthening the Partnership

In the commercial area, the companies have developed software for third-party access (TPA) and master data agreements that permit Veeva or IQVIA data to be best integrated with each other's services or software in customer instances, including the integration of IQVIA data in the Veeva network for master data management (MDM), also Veeva Nitro for Veeva AI and analytics. Additionally, the use of Veeva data in IQVIA’s marketing products and services, IQVIA has participated in the Veeva AI, services partner programs, and technology to boost customer merger between IQVIA analytics and Veeva software. Also, including IQVIA agentic AI, IQVIA commercial orchestration offerings, and IQVIA information management (consisting of MDM). The customers will receive the fastest, seamless process to take TPAs for projects.

In the clinical area, IQVIA became a part of Veeva’s CRO clinical data partner program and can accelerate the Veeva clinical suite to implement clinical trials with the Veeva software products involving study forms with Veeva EDC. In this area, with this partnership, the customers will get an advantage from IQVIA’s clinical data management and clinical technology solutions. Also, the customers will benefit from EDC programming expertise with Veeva software to elevate study locks, data delivery, and database build.

Views and Statements from the Company Leaders

CEO and Founder of Veeva, Peter Gassner, said, “We promise to contribute to frictionless product and services merger with IQVIA for the best of our joint customers and the industry. I am thrilled about the capability of our marketing and clinical collaboration to discover prominent value for our joint customers.”

Chairman and CEO of IQVIA, Ari Bousbib, said, “Veeva’s and IQVIA’s collaboration has introduced excellent potential in AI, services, technology, and information for our joint clients. This will provide IQVIA customers on Veeva platforms to leverage clinical development, also introduce treatments to market more effectively, and enhance availability to innovations for patients.”